[{"id":"695ed227-f983-42a5-8c99-0c2af02274f1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03014804","created_at":"2021-01-18T14:50:13.156Z","updated_at":"2025-02-25T14:37:07.214Z","phase":"Phase 2","brief_title":"Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma","source_id_and_acronym":"NCT03014804","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" PD-L1 • MGMT","pipe":" | ","alterations":" MGMT promoter methylation","tags":["PD-L1 • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGMT promoter methylation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • DCVax-L (autologous dendritic cell vaccine leaded with autologous tumor cell lysate)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/01/2019","start_date":" 12/01/2019","primary_txt":" Primary completion: 12/01/2020","primary_completion_date":" 12/01/2020","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2020-07-24"}]